Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Single-Arm, Phase II Clinical Study of Sacituzumab Tirumotecan Plus Pembrolizumab as Second-Line Treatment for Advanced Biliary Tract Cancer

NCT07850791 is registered in ClinicalTrials.gov with Haitao Zhao, MD as lead sponsor.

NCT NCT07850791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07850791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Single-Arm, Phase II Clinical Study of Sacituzumab Tirumotecan Plus Pembrolizumab as Second-Line Treatment for Advanced Biliary Tract Cancer
Lead sponsor
Haitao Zhao, MD
Phase
Phase 2
Overall status
Recruiting
Start date
October 31, 2026
Completion date
December 31, 2029
Enrollment
38 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer (btc)